Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
Lillian Y LaiMary K OerlineMegan E V CaramPhoebe A TsaoSamuel R KaufmanBrent K HollenbeckVahakn B ShahinianPublished in: Journal of the National Cancer Institute (2022)
Careful monitoring and management of men on abiraterone or enzalutamide through team-based approaches are critical.